Coronary restenosis is a medical condition characterized by the narrowing or blockage of coronary arteries after an initial intervention, such as angioplasty or stent placement, to treat coronary artery disease. Despite the success of these procedures in restoring blood flow to the heart, restenosis can occur over time, leading to recurrent symptoms like chest pain or angina. The underlying mechanism involves the re-growth of tissue within the treated artery, known as neointimal hyperplasia, or the recurrence of atherosclerotic plaque. Various factors contribute to the development of coronary restenosis, including patient-specific characteristics, procedural techniques, and the type of devices used. Researchers and clinicians continually strive to develop strategies to minimize the risk of restenosis, such as drug-eluting stents that release medication to inhibit tissue growth. Management often involves a combination of medications and lifestyle modifications to address the underlying coronary artery disease and reduce the likelihood of recurrence, highlighting the ongoing challenges in optimizing long-term outcomes for patients with cardiovascular conditions.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India